PERCF (Percheron Therapeutics) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Percheron Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Percheron Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Percheron Therapeutics's long-term debt to total assets ratio declined from Dec. 2022 (0.01) to Dec. 2023 (0.00). It may suggest that Percheron Therapeutics is progressively becoming less dependent on debt to grow their business.

Percheron Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Percheron Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Percheron Therapeutics LT-Debt-to-Total-Asset Chart

Percheron Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.01

Percheron Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	-	-	-

Percheron Therapeutics LT-Debt-to-Total-Asset Calculation

Percheron Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (A: Jun. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2023 )	/	Total Assets (A: Jun. 2023 )
	=	0.032	/	8.619
	=

Percheron Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0	/	13.373
	=

Percheron Therapeutics (OTCPK:PERCF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Percheron Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Percheron Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Percheron Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Percheron Therapeutics Ltd (OTCPK:PERCF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

AWY0:Germany AWY0:Germany PER:Australia

Address

14 Wallace Avenue, LEVEL 1, Toorak, VIC, AUS, 3142

Website

https://www.percherontx.com

Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.